UCB (OTCMKTS:UCBJY) Reaches New 1-Year High - Still a Buy?

Key Points

• UCB SA has reached a new 52-week high of $118.15, with the stock last trading at $118.04 and a volume of 6,246 shares.
• Equities research analysts have upgraded UCB's rating to "strong-buy", reflecting positive sentiment with a consensus rating of "Strong Buy."
• The company specializes in developing biopharmaceutical products for neurology and immunology diseases, including notable medications like Cimzia and Vimpat.

UCB SA (OTCMKTS:UCBJY - Get Free Report) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $118.15 and last traded at $118.04, with a volume of 6246 shares trading hands. The stock had previously closed at $115.55.

Analysts Set New Price Targets

UCBJY has been the topic of a number of analyst reports. The Goldman Sachs Group raised UCB to a "strong-buy" rating in a research note on Wednesday, July 16th. Zacks Research raised UCB from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 29th. Two analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Strong Buy".

UCB Stock Up 2.0%

The company has a quick ratio of 0.99, a current ratio of 1.36 and a debt-to-equity ratio of 0.30. The business has a fifty day moving average of $107.56 and a 200-day moving average of $96.49.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.